Design Therapeutics Income Statement (2020-2021) | DSGN

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021
Revenue & Cost
Revenue 0.14M0.03M0.02M0.03M
Operating Items
Research & Development 0.38M1.06M1.91M2.71M
Wages, Salaries and Other 0.10M0.22M
Selling, General & Administrative 0.39M0.43M0.49M1.19M
Operating Expenses 0.77M1.49M2.40M3.89M
Operating Income -0.62M-1.46M-2.38M-3.86M
EBIT -0.62M-1.46M-2.38M-3.86M
Non-operating items
Other Non Operating Income -0.04M0.02M0.06M0.01M
Non Operating Income -0.04M0.02M0.06M0.01M
Net income details
EBT -0.62M-1.46M-2.38M-3.86M
Profit After Tax -0.66M-1.44M-2.32M-3.85M
Income from Continuing Operations -0.62M-1.46M-2.38M-3.86M
Consolidated Net Income -0.62M-1.46M-2.38M-3.86M
Income towards Parent Company -0.62M-1.46M-2.38M-3.86M
Net Income towards Common Stockholders -0.62M-1.46M-2.38M-3.86M
Additional items
EPS (Basic) -0.04-0.06-0.09-0.35
Shares Outstanding (Weighted Average) 53.82M53.82M55.62M55.62M
Shares Outstanding (Diluted Average) 55.08M55.16M
EBITDA -0.62M-1.46M-2.38M-3.86M